The Effect of Olanzapine Treatment on m-Chlorophenylpiperazine-Induced Hormone Release in Schizophrenia
The DOI matches its Crossref record.
Abstract
In addition to dopamine, serotonin (5-hydroxytryptamine, 5-HT) has been reported to play an important role in schizophrenia. Besides blocking dopamine, atypical antipsychotics also block 5-HT receptors. The clinical efficacy of the atypical antipsychotic clozapine is associated with the 5-HT antagonistic action of the drug and a high serotonergic tone before treatment. The atypical antipsychotic olanzapine has a receptor-binding profile similar to that of clozapine. The present study investigated whether treatment with olanzapine blocks hormone release induced by the 5-HT2c agonist m-chlorophenylpiperazine (m-CPP) and, if so, whether this 5-HT antagonistic effect is related to treatment response. Eighteen male schizophrenic patients participated in this study. All patients were challenged with m-CPP (0.5 mg/kg orally) in a double-blind, randomized, placebo-controlled design after a drug-free period of at least 2 weeks. Adrenocorticotropic hormone (ACTH), cortisol, and prolactin plasma levels were measured every 30 minutes up to 210 minutes after challenge. Patients were treated for 6 weeks with 10 mg olanzapine daily in an open design, after which the challenge tests were repeated. Olanzapine significantly blocked m-CPP-induced ACTH, cortisol, and prolactin release, suggesting that it is a potent 5-HT2c antagonist in vivo. This 5-HT antagonistic effect of olanzapine was not significantly correlated with treatment response. Also, no significant correlation was found between m-CPP-induced hormone release before treatment and clinical response after treatment with olanzapine. These findings suggest that olanzapine is a potent 5-HT2c antagonist in vivo but that this is unrelated to its clinical efficacy in this nonrefractory sample of schizophrenic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia
Walker, E., Mittal, V., & Tessner, K. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.4.022007.141248 · Cited by 615
Mondelli, V., Dazzan, P., Hepgul, N., Di Forti, M., Aas, M., D'Albenzio, A., Di Nicola, M., Fisher, H., Handley, R., Marques, T. R., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.013 · Cited by 278
“Indeed, previous studies have shown that treatment with atypical antipsychotics, such as olanzapine, clozapine or risperidone, causes reduction in cortisol levels in patients with schizophrenia as well as in healthy controls (Cohrs et al., 2006; Hatzimanolis et al., 1998; Mann et al., 2006; Markianos et al., 1999; Mel…”
Sautter, F. J., Bissette, G., Wiley, J., Manguno-Mire, G., Schoenbachler, B., Myers, L., Johnson, J. E., Cerbone, A., & Malaspina, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00571-7 · Cited by 162
Cohrs, S., Röher, C., Jordan, W., Meier, A., Huether, G., Wuttke, W., Rüther, E., & Rodenbeck, A. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0279-x · Cited by 141
Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth.
Walker, E. F., Brennan, P. A., Esterberg, M., Brasfield, J., Pearce, B., & Compton, M. T. (2010) · Journal of Abnormal Psychology · doi:10.1037/a0018399 · Cited by 127
Metadata
- Authors
- Scheepers, F. E., Gispen de Wied, C. C., & Kahn, R. S.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2001-12
- Volume
- 21
- Issue
- 6
- Pages
- 575-582
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2330012262
- Cited by
- 40
- References
- 0
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Olanzapine Treatment on m-Chlorophenylpiperazine-Induced Hormone Release in Schizophrenia. https://app.cochat.ai/papers/10.1097/00004714-200112000-00006
- The paper
- Scheepers, F. E., Gispen de Wied, C. C., & Kahn, R. S. (2001). The Effect of Olanzapine Treatment on m-Chlorophenylpiperazine-Induced Hormone Release in Schizophrenia. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-200112000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.